Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies

Molecular Biology of the Cell

Volumn 9, Issue 5, 1998, Pages 1007-1023

  Lorenz, Peter ^a   Baker, Brenda F ^b   Bennett, C Frank ^b   Spector, David L ^a  

^a Simons Center for Quantitative Biology   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID;

ARTICLE; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CELL NUCLEUS MATRIX; CELLULAR DISTRIBUTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

EID: 0031667333     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.9.5.1007     Document Type: Article

References (71)

1. Abdul-Manan, N., and Williams, K.R. (1996) hnRNP A1 binds promiscuously to oligoribonucleotides: utilization of random and homo-oligonucleotides to discriminate sequence from base-specific binding. Nucleic Acids Res. 24, 4063-4070.
2. Agrawal, S. (1996). Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14, 376-387.
3. Agrawal, S., and Iyer, R.P. (1995). Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6, 12-19.
4. Ahn, J.H., and Hayward, G.S. (1997). The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 71, 4599-4613.
5. Andrade, L.E., Tan, E.M., and Chan, E.K. (1993). Immunocytochemical analysis of the coiled body in the cell cycle and during cell proliferation. Proc. Natl. Acad. Sci. USA 90, 1947-1951.
6. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M., and Bennett, C.F. (1997). 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
7. Beaucage, S.L., and Iyer, R.P. (1992). Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48, 2223-2311.
8. Beltinger, C. et al. (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
9. Bennett, C.F., Chiang, M.Y., Chan, H., Shoemaker, J.E., and Mirabelli, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 47, 1023-1033.
10. Bennett, C.F., Condon, T.P., Grimm, S., Chan, H., and Chiang, M.Y. (1994). Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 152, 3530-3540.
11. Bennett, C.F. et al. (1997) An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280, 988-1000.
12. Berezney, R. (1991). The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell. Biochem. 47, 109-123.
13. Bohmann, K., Ferreira, J., Santama, N., Weis, K., and Lamond, A.I. (1995). Molecular analysis of the coiled body. J. Cell Sci. Suppl. 19, 107-113.
14. Boussif, O., Lezoualcqh, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., and Behr, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: poly-ethylenimine. Proc. Natl. Acad. Sci. USA 92, 7297-7301.
15. Brasch, K., and Ochs, R.L. (1992). Nuclear bodies (NBs): a newly "rediscovered" organelle. Exp. Cell Res. 202, 211-223.
16. Brown, D.A., Kang, S.H., Gryaznov, S.M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., and Nerenberg, M.I. (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
17. Burd, C.G., and Dreyfuss, G. (1994). RNA binding specificity of hnRNP Al: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J. 13, 1197-1204.
18. Chaly, N., Setterfield, G., Kaplan, J.G., and Brown, D.L. (1983). Nuclear bodies in mouse splenic lymphocytes: II. Cytochemistry and autoradiography during stimulation by concanavalin A. Biol. Cell 49, 35-43.
19. Chiang, M.Y., Chan, H., Zounes, M.A., Freier, S.M., Lima, W.F., and Bennett, C.F. (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266, 18162-18171.
20. Chin, D.J., Green, G.A., Zon, G., Szoka F.C., Jr, and Straubinger, R.M. (1990). Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol 2, 1091-1100.
21. Clarenc, J.P., Lebleu, B., and Leonetti, J.P. (1993). Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. J. Biol. Chem. 268, 5600-5604.
22. Coats, S., Flanagan, W.M., Nourse, J., and Roberts, J.M. (1996). Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880.
23. Condon, T.P., and Bennett, C.F. (1996). Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J. Biol. Chem. 271, 30398-30403.
24. Crooke, S.T. (1996). Progress in antisense therapeutics. Med. Res. Rev. 16, 319-344.
25. Crooke, S.T. (1997). Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv. Pharmacol. 40, 1-49.
26. Crooke, S.T., and Bennett, C.F. (1996). Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 107-129.
27. Dean, N.M., and McKay, R. (1994). Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 11762-11766.
28. Dean, N.M., McKay, R., Miraglia, L., Geiger, T., Muller, M., Fabbro, D., and Bennett, C.F. (1996a). Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Biochem. Soc. Trans. 24, 623-629.
29. Dean, N. et al. (1996b) Inhibition of Growth of Human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 56, 3499-3507.
30. Fey, E.G., Krochmalnic, G., and Penman, S. (1986). The nonchromatin substructures of the nucleus: the ribonucleoprotein (RNP)-containing and RNP-depleted matrices analyzed by sequential fractionation and resinless section electron microscopy. J. Cell Biol. 102, 1654-1665.
31. Fisher, T.L., Terhorst, T., Cao, X., and Wagner, R.W. (1993). Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21, 3857-3865.
32. Flanagan, W.M., Kothavale, A., and Wagner, R.W. (1996). Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency. Nucleic Acids Res. 24, 2936-2941.
33. Fu, X.-D., and Maniatis, T. (1990). Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature 343, 437-441.
34. Giles, R.V., Spiller, D.G., and Tidd, D.M. (1995). Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5, 23-31.
35. Haaf, T., and Ward, D.C. (1996). Inhibition of RNA polymerase II transcription causes chromatin decondensation, loss of nucleolar structure, and dispersion of chromosomal domains. Exp. Cell Res. 224, 163-173.
36. Habets, W.J., Hoet, M.H., De Jong, B.A., Van der Kemp, A., and Van Venrooij, W.J. (1989). Mapping of B cell epitopes on small nuclear ribonucleoproteins that react with human autoantibodies as well as with experimentally-induced mouse monoclonal antibodies. J. Immunol. 143, 2560-2566.
37. Hougaard, D.M. (1992). Polyamine cytochemistry: localization and possible functions of polyamines. Int. Rev. Cytol. 138, 51-88.
38. Huang, S., Deerinck, T.J., Ellisman, M.H., and Spector, D.L. (1994). In vivo analysis of the stability and transport of nuclear poly(A)+ RNA. J. Cell Biol. 126, 877-899.
39. Huang, S., and Spector, D.L. (1996). Inrron-dependent recruitment of pre-mRNA splicing factors to sites of transcription. J. Cell Biol. 333, 719-732.
40. Ishov, A.M., and Maul, G.G. (1996). The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J. Cell Biol. 134, 815-826.
41. Koken, M.H. et al. (1994) The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13, 1073-1083.
42. Krainer, A.R. (1988). Pre-mRNA splicing by complementation with purified human Ul, U2, U4/U6 and US snRNPs. Nucleic Acids Res. 16, 9415-9429.
43. Leonetti, J.P., Mechti, N., Degols, G., Gagnor, C., and Lebleu, B. (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 88, 2702-2706.
44. Luger, S.M., Ratajczak, J., Ratajczak, M.Z., Kuczynski, W.I., DiPaola, R.S., Ngo, W., Clevenger, C.V., and Gewirtz, A.M. (1996) A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood 87, 1326-1334.
45. Mattern, K.A., van Goethem, R.E., de Jong, L., and van Driel, R. (1997). Major internal nuclear matrix proteins are common to different human cell types. J. Cell. Biochem. 65, 42-52.
46. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M., and Fabbro, D. (1996). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2, 668-675.
47. Moroi, Y., Peebles, C., Fritzler, M.J., Steigerwald, J., and Tan, E.M. (1980). Autoantibody to centromere (kinetochore) in scleroderma sera. Proc. Natl. Acad. Sci. USA 77, 1627-1631.
48. Nestle, F.O., Mitra, R.S., Bennett, C.F., Chan, H., and Nickoloff, B.J. (1994). Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 103, 569-575.
49. Neurath, M.F., Pettersson, S., Meyer zum Buschenfelde, K.H., and Strober, W. (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2, 998-1004.
50. O'Keefe, R.T., Henderson, S.C., and Spector, D.L. (1992) Dynamic organization of DNA replication in mammalian cell nuclei: spatially and temporally defined replication of chromosome-specific alpha-satellite DNA sequences. J. Cell Biol. 116, 1095-1110.
51. Ochs, R.L., Stein T.W., Jr, Andrade, L.E., Gallo, D., Chan, E.K., Tan, E.M., and Brasch, K. (1995). Formation of nuclear bodies in hepatocytes of estrogen-treated roosters. Mol. Biol. Cell 6, 345-356.
52. Offensperger, W.B., Offensperger, S., Walter, E, Teubner, K., Igloi, G., Blum, H.E., and Gerok, W. (1993). In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 32, 1257-1262.
53. Piñol-Roma, S., and Dreyfuss, G. (1992). Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355, 730-732.
54. Roch, A.M., Nicolas, M.T., and Quash, G. (1997). Ultrastructural immunolocalizarion of polyamines in HeLa cells subjected to fast-freezing fixation and freeze substitution. Histochem. Cell Biol. 107, 303-312.
55. Sharma, H.W., and Narayanan, R. (1995). The therapeutic potential of antisense oligonucleotides. Bioessays 17, 1055-1063.
56. Shoeman, R.L., Hartig, R., Huang, Y., Grueb, S., and Traub, P. (1997). Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7, 291-308.
57. Shuttleworth, J., and Colman, A. (1988). Antisense oligonucleotide-directed cleavage of mRNA in Xenopus oocytes and eggs. EMBO J. 7, 427-434.
58. Spector, D.L. (1993). Macromolecular domains within the cell nucleus. Annu. Rev. Cell Biol. 9, 265-315.
59. Spector, D.L., Fu, X.-D., and Maniatis, T. (1991). Associations between distinct pre-mRNA splicing components and the cell nucleus. EMBO J. 10, 3467-3481.
60. Spector, D.L., Lark, G., and Huang, S. (1992). Differences in snRNP localization between transformed and nontransformed cells. Mol. Biol. Cell 3, 555-569.
61. Stein, C.A. (1996). Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 14, 147-149.
62. Stepkowski, S.M., Tu, Y., Condon, T.P., and Bennett, C.F. (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153, 5336-5346.
63. Stuurman, N., de Graaf, A., Floore, A., Josso, A., Humbel, B., de Jong, L., and van Driel, R. (1992). A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J. Cell Sci. 302, 773-784.
64. Tarrason, G., Bellido, D., Eritja, R., Vilaro, S., and Piulats, J. (1995). Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake. Antisense Res. Dev. 5, 193-201.
65. Terris, B., Baldin, V., Dubois, S., Degott, C., Flejou, J.F., Henin, D., and Dejean, A. (1995). PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 55, 1590-1597.
66. Thierry, A.R., and Dritschilo, A. (1992). Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20, 5691-5698.
67. Wagner, R.W., and Flanagan, W.M. (1997). Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today 3, 31-38.
68. Wagner, R.W., Matteucci, M.D., Grant, D., Huang, T., and Froehler, B.C. (1996). Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat. Biotechnol. 14, 840-844.
69. Wagner, R.W., Matteucci, M.D., Lewis, J.G, Gutierrez, A.J, Moulds, C., and Froehler, B.C. (1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510-1513.
70. Webb, A., Cunningham, D., Cotter, F., Clarke, P.A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141.
71. Weidner, D.A., Valdez, B.C., Henning, D., Greenberg, S., and Busch, H. (1995). Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett. 366, 146-150.